On January 8, 2026 Biomunex Pharmaceuticals, a biopharmaceutical company specializing in the development of next generation immunotherapies based on the discovery and development of bispecific and multispecific antibodies, today announces its participation at the 11th Annual Oncology Innovation Forum, organized by Sachs Associates, on the 10th of January at the Marines’ Memorial Club in San Francisco (USA).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The 2026 Oncology Innovation Forum programme is designed to discuss key industry trends and milestones; it will feature high-level keynotes and panel discussions covering the latest trends in Pharma and Biotech business development, modalities, targets, and investment. Biomunex’s invitation highlights the company’s commitment to innovative therapeutic approaches in oncology.
Invited for an oral communication, Dr. Simon Plyte, Biomunex CSO (Chief Scientific Officer), will present the Company and its unique and highly differentiated MAIT engager Platform. MAIT engagers are expected to overcome some of the limitations of current CD3+ TCEs, including activation of regulatory T cells (Tregs) and cytokine release syndrome, serious side effects that are difficult to manage for cancer patients.
MAIT engagers, that are as potent as classical CD3+ TCE, have the potential to bring significantly improved safety, providing a larger therapeutic window in solid tumor types. Moreover, MAIT engagers can effectively induce the "SPARK effect" (tumor cytotoxicity with induced secondary immune response), enabling long-term durable anti-cancer response.
Biomunex is notably developing a portfolio of MAIT engager drug candidates, a new therapeutic class in immuno-oncology, that are highly differentiated from classical CD3+ TCEs. MAIT engagers are bispecific antibodies that identify, mobilize and bridge MAIT cells (Mucosal-Associated Invariant T cells), present in all body and particularly in mucosal and barrier tissues, to cancer cells, resulting in MAIT cell activation and directed killing of tumors.
MAIT engagers could become a breakthrough approach in the treatment of many cancers, particularly in solid tumors, significantly widening the therapeutic window.
Based on the proprietary "Plug-and-Play" BiXAb bispecific antibody platform that enables the generation of breakthrough immunotherapies faster than most other bispecific platforms in the field and with excellent drug-like properties and high industrial yield, the Biomunex’ MAIT engager programmes will pave the way for a series of innovative new immunotherapeutics for the treatment of several cancers.
Dr. Pierre-Emmanuel Gerard, Biomunex’s founder and President, concludes: "Our presentation during the 11th Annual Oncology Innovation Forum will enable us to illustrate the differentiation of MAIT engagers and how this innovative and highly promising approach for the treatment of cancer could potentially redefine the standard of care for solid tumors."
Details about Biomunex’ presentations at 11th Annual Oncology Innovation Forum
Oral presentation:
Saturday 10th January 2026, 2:55 PST
Room: Heritage
Marines’ Memorial Club, San Francisco, USA